USPTO Issues Notice of Allowance to BRAINBox Solutions to Grant Broad U.S. Patent Covering Biomarkers that Correlate to MRI Neuroimaging Findings
RICHMOND, Va., March 17, 2023 /PRNewswire/ -- BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods. The patent is part of the company's extensive and growing intellectual property portfolio covering the use of novel biomarkers in combination with functional tests to diagnose individuals with concussion (mild traumatic brain injury or acute traumatic encephalopathy, ATE) and assess their risk of chronic injury.
- RICHMOND, Va., March 17, 2023 /PRNewswire/ -- BRAINBox Solutions today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance to issue to the company a broad patent covering a specific set of biomarkers that correlate to specific neuroimaging findings by standard or advanced MRI methods.
- "This new patent, and our broader portfolio, underlie the BRAINBox TBI family of diagnostic/prognostic point-of-care or main lab delivered tests we are developing for ATE," said Donna Edmonds, CEO of BRAINBox Solutions.
- The Initial BRAINBox ATE test will include a panel of blood biomarkers and a battery of neurocognitive tests, combined in an easy-to-use application.
- The new patent will cover the use of eight biomarkers, including Aldolase C (ALDOC) and Neurogranin (NRGN).